From 2011 to 2017, there was an increase in gross annual expenditures on multiple sclerosis (MS) disease-modifying therapies (DMTs), with increased spending mainly driven by increases in per-prescription costs.
The researchers observed significant associations between cannabis use and the local legal status of cannabis among patients with MS.
Despite its prevalence, many myths surround multiple sclerosis. We review 5 common misconceptions among patients.
There is uncertainty regarding the effect of exercise and other interventions on the prevention of falls in patients with multiple sclerosis.
For pediatric patients with multiple sclerosis, there are more admissions among girls and among white children.
The FDA has approved the first generic versions of fingolimod for the treatment of relapsing forms of multiple sclerosis in adults.
The risk for disability worsening is increased for individuals with multiple sclerosis (MS) and comorbid depression.
Early initiation of highly effective escalation therapies in pediatric patients with MS is associated with reduced cognitive impairment and may prevent cognitive decline.
Many multiple sclerosis (MS) patients are considering autologous hematopoietic stem cell transplantation (aHSCT) as a treatment option.
Cortical atrophy and cognitive decline accelerate together during the course of multiple sclerosis.
